Friday, August 29, 2014

Aeterna presents “no benefit” results for perifosine

June 4, 2012 by · Leave a Comment 

Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) has presented data from a Phase 3 clinical trial for its perifosine drug in refractory colorectal cancer at the American Society of Clinical Oncology.

Data showed no benefit in overall survival when adding perifosine to capecitabine in the refractory colorectal cancer setting, confirming top line results previously disclosed in April.

Despite the disappointing data, CEO Juergen Engel said the results “do not deter us from our decision to continue the Phase 3 trial in multiple myeloma, which was based first and foremost on existing solid preclinical and clinical data, and on the support for this drug among key opinion leaders in this field.”

“Additionally, we believe that market opportunity, examples of other drugs enjoying success after facing setbacks, as well as the reasonable investment required to move forward with this study up to the predefined interim analysis, also makes this a sound decision for the company,” he added.

Print Friendly

Comments are closed.

Email Newsletters with Constant Contact
Google+